Cecilia Jones
Director of Finance/CFO bei AGIOS PHARMACEUTICALS, INC.
Vermögen: 433 922 $ am 31.03.2024
Profil
Cecilia Jones is currently the Chief Financial Officer at Agios Pharmaceuticals, Inc. Her former jobs include Senior Director-Corporate Finance at Biogen, Inc. from 2015 to 2019, and Director-International Finance at Genzyme Corp.
from 2003 to 2009.
She also served as Treasurer, Chief Financial & Accounting Officer at LogicBio Therapeutics, Inc. from 2021 to 2022.
Jones holds an MBA from Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.03.2024 | 14 840 ( 0,03% ) | 433 922 $ | 31.03.2024 |
Aktive Positionen von Cecilia Jones
| Unternehmen | Position | Beginn |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Director of Finance/CFO | 26.09.2022 |
Ehemalige bekannte Positionen von Cecilia Jones
| Unternehmen | Position | Ende |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Director of Finance/CFO | 23.09.2022 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.11.2009 |
| BIOGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Cecilia Jones
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
